Tajikistan Medical Device Registration Certificate 2026: Five-Year Validity and Re-Registration Planning

1. Key takeaways

The validity period of a medical device registration certificate in Tajikistan is five years, and this conclusion comes from statutory-level text. Article 17(6) of Law No. 1893 provides: for registered medicines, pharmaceutical substances, medical goods and parapharmaceuticals, a registration certificate in a format determined by the authorized state body in the healthcare sphere is issued with a validity period of five years; the registration certificate holder bears responsibility for the quality, effectiveness and safety of the registered materials. GRZAN states clearly here: the claim circulating in the market that the Tajikistan registration certificate is valid for 3 years is not adopted by us; at the same time, a five-year validity does not mean five years without risk — Article 21 lists 12 statutory grounds for withdrawal from circulation.

2. Legal basis

3. Expert insights

Insight 1: The five-year validity is express statutory text, not a departmental rule or practical convention. This matters greatly in dispute handling. Article 17(6) sits at the statutory level and prevails over any departmental normative document. When reviewing Tajikistan registration certificates received by clients, GRZAN, upon finding a validity period inconsistent with five years, raises the statutory text directly as the basis for negotiation — because the wording of the law is a validity period of five years, leaving no delegated space for determination otherwise by the competent authority.

Insight 2: The three responsibilities of the certificate holder — quality, effectiveness and safety — correspond one-to-one with the requirements of Article 15. Article 15(1) provides that medicines, medical goods and parapharmaceuticals must be of high quality, effective and safe, and comply with the general pharmacopoeia provisions, the state pharmacopoeia, quality control normative documents and other standards applied by the supervisory body. Article 17(6) converts these three requirements into the statutory responsibility of the certificate holder. The structural implication is that the conformity determination made at registration is continuously presumed, throughout the five-year validity, to be a continuing obligation of the certificate holder; once non-conformity appears, the withdrawal mechanism of Article 21 is triggered.

Insight 3: Article 21(1), item 3 reveals a time trap that is easily overlooked. That provision requires withdrawal from circulation where the registration and re-registration period of medicines, medical goods and parapharmaceuticals has expired before their import into Tajikistan. This means the reference point for judging certificate validity is neither the moment of sale nor the completion of customs clearance, but the point before import into Tajikistan. For goods transported overland from China to Tajikistan through third countries, the transport cycle can span several weeks; if the certificate has expired by the time the goods arrive at the border crossing, the goods fall into the statutory grounds for withdrawal from circulation. GRZAN recommends building the transport cycle into the safety margin when scheduling.

Insight 4: Article 17(10) and Article 17(12) list the procedure-making powers for medicines and for medical goods separately. Paragraph 10 addresses medicines and paragraph 12 addresses medical goods and parapharmaceuticals, both pointing to the development and approval power of the Ministry of Health. This separation shows the legislator intended to keep device procedure documents distinct from those for medicines; when requesting procedure documents, enterprises should expressly request those applicable to medical goods rather than medicines, to avoid receiving an inapplicable version.

4. Practical recommendations

1. Plan the ledger backward from the five-year validity, but leave a transport margin. GRZAN recommends setting the re-registration start date 6 to 9 months before expiry, and including the overland transport cycle from China to Tajikistan in the safety margin calculation, to avoid falling into the scenario of Article 21(1), item 3.
2. Request separately the procedure documents applicable to medical goods. Under Article 17(12), request the registration, re-registration and change procedures for medical goods from the Ministry of Health; do not reuse the medicines version (Article 17(10)).
3. Write the three responsibilities of the certificate holder into quality system documents. The quality, effectiveness and safety responsibilities of Article 17(6) should be implemented as a traceable responsibility matrix within the certificate-holding party quality management system, covering change control, complaint handling and adverse event reporting.
4. Check both format and validity on the original certificate. Article 17(6) requires the certificate format to be determined by the Ministry of Health; in the certificate acceptance checklist of GRZAN, format conformity and the five-year validity are two parallel mandatory checkpoints.

5. Verification checklist

• □ Confirmed the certificate states a validity period of five years (Article 17(6))
• □ Confirmed the certificate format is determined by the authorized state body in the healthcare sphere
• □ Implemented the certificate holder responsibilities for quality, effectiveness and safety in the quality system
• □ Planned the re-registration start date backward from the five-year validity, including the third-country transit cycle
• □ Requested separately the registration, re-registration and change procedure documents applicable to medical goods (Article 17(12))
• □ Established a self-check mechanism for the 12 withdrawal grounds of Article 21(1)
• □ Confirmed the registered products have been entered by the supervisory body into the State Register of Medicines (Article 17(8))

Regulatory information verified as of October 29, 2026.

In the Central Asian market, the core capabilities of GRZAN concentrate on three points: first, distinguishing the different legal status of each market within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states offering a dual choice between the national track and the union track; Uzbekistan is an observer state with only the national track; Tajikistan and Turkmenistan are outside the union framework and must follow purely national procedures. Second, local authorized representative services, acting as the statutory representative of manufacturers in these countries and undertaking registration submission, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com